EMA/PE/0000227908

Opinion/decision on a Paediatric investigation plan (PIP): Voydeya, danicopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000227558

Opinion/decision on a Paediatric investigation plan (PIP): Zeftera (previously Zevtera), ceftobiprole medocaril (sodium), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000227526

EMA/PE/0000227462

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000227425

Opinion/decision on a Paediatric investigation plan (PIP): Symkevi, tezacaftor,ivacaftor, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000227394

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 7, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: EMA/PE/0000226957

Draft guidance on the conduct of clinical trials during public health emergencies

Records of data processing activity for the handling the contribution towards commuting costs